Partner Content Partner Content Topics Presented this February 2018 at RNA Therapeutics RNA Therapeutics 2018
Partner Content Partner Content SMi Group: Exclusive Speaker Interview with Professor Nagy H... RNA Therapeutics
Partner Content Partner Content New Confirmed Delegates & Speakers for RNA Therapeutics RNA Therapeutics
Partner Content Partner Content ProQR Therapeutics: RNA Therapeutics for Patients with Cysti... RNA Therapeutics
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.